Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15303437 | 1.00 | KDM4E (0.35) | KDM4EMCOLN3MMP13ELANEAR | |
| SCHEMBL30939625 | 0.93 | KDM4E (0.35) | KDM4EMCOLN3MMP13ELANEAR | |
| SCHEMBL9904969 | 0.93 | KDM4E (0.35) | KDM4EMCOLN3MMP13ELANEAR | |
| SCHEMBL15303543 | 0.86 | KDM4E (0.38) | KDM4EMCOLN3MMP13 | |
| SCHEMBL9924311 | 0.86 | KDM4E (0.34) | KDM4EMCOLN3MMP13 | |
| SCHEMBL30939527 | 0.86 | KDM4E (0.34) | KDM4EMCOLN3MMP13 | |
| SCHEMBL21116329 | 0.83 | AR (0.39) | KDM4EMCOLN3MMP13ELANEAR | |
| SCHEMBL17180633 | 0.82 | KDM4E (0.35) | KDM4EMCOLN3 | |
| SCHEMBL30939589 | 0.81 | MMP13 (0.36) | MMP13ELANEAR | |
| SCHEMBL14158671 | 0.81 | MMP13 (0.36) | MMP13ELANEAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118267386-A | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-108472288-B | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | KDM4E 1460/4885MCOLN3 288/4885MMP13 3782/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | KDM4E 1460/4885MCOLN3 288/4885MMP13 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.